AI assistant
Armata Pharmaceuticals, Inc. — Director's Dealing 2008
Feb 8, 2008
34152_dirs_2008-02-08_2a1cc124-2a7b-4611-a9f5-2e60b69f66c9.zip
Director's Dealing
Open in viewerOpens in your device viewer
SEC Form 4 — Statement of Changes in Beneficial Ownership
Issuer: TARGETED GENETICS CORP /WA/ (TGEN)
CIK: 0000921114
Period of Report: 2008-02-06
Reporting Person: MARXE AUSTIN W & GREENHOUSE DAVID M (10% Owner)
Non-Derivative Transactions
| Date | Security | Code | Shares | Price | A/D | Holdings After | Ownership |
|---|---|---|---|---|---|---|---|
| 2008-02-06 | Common Stock | S | 42800 | $1.1496 | Disposed | 2581297 | Indirect |
Footnotes
F1: This is a joint filing by Austin W. Marxe (Marxe) and David M. Greenhouse (Greenhouse). They share voting and investment control over all securities owned by Special Situations Fund III QP, L.P (SSFQP) and Special Situations Life Sciences Fund, L.P. (LS), respectively. 1,937,920 shares of Common Stock are owned by SSFQP and 643,377 shares of Common Stock are owned by LS. The interest of Marxe and Greenhouse in the shares of Common Stock owned by SSFQP and LS is limited to the extent of his pecuniary interest.